MV4-11 cell

SKU:BHC11100404
Bulk Pricing Research Validated
Overview
Click light‑blue chips for details

MV4-11 cell is a Myelomonocytic, biphenotypic cell line derived from Caucasian (Male). It is commonly used as an in vitro model for 1 research. Growth characteristics: Suspension, Round cells. Supplied as cryopreserved cells with accompanying batch CoA and quality-control documentation.

Species Human
Disease model Acute monocytic leukemia
Morphology Round cells
Growth Properties Suspension
Tissue Blood
Available Options

This cell line is available in the U.S. For non-profit users, please sign and submit the Non-Profit Supply Agreement to orders@biohippo.com before placing an order. For commercial users, please complete the CLEAR Form before ordering, as additional usage fees may apply based on the intended use. For further details, please contact orders@biohippo.com. Products ship after the required agreement is completed; typical delivery is 2–3 business days. Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 10^6 cells for adherent lines or 5 × 10^6 cells for suspension lines (refer to the batch CoA for details).

Options selector
Catalog no. Size
300295 1 cryovial
Field Specification
Species Human
The MV-4-11 cell line, isolated from the blast cells of a child with biphenotypic B-myelomonocytic leukemia, serves as a critical resource in the study of acute leukemias, particularly acute myeloid leukemia (AML). MV4-11 cells are characterized by their high proliferation rate and the presence of certain genetic abnormalities. A translocation between chromosomes 4 and 11 leads to the creation of the MLL-AF4 fusion gene, which plays a crucial role in leukemogenesis and contributes to the aggressive nature of leukemia. The presence of the MLL-AF4 fusion gene makes these cells particularly relevant for understanding the molecular mechanisms underlying leukemogenesis and studies on targeted therapies that aim to disrupt the function of this oncogenic fusion protein. Additionally, MV4-11 cells can be used to study the biology of leukemia stem cells, drug resistance mechanisms, and the role of the bone marrow microenvironment in leukemia progression. The cell line is further instrumental in metabolomics and transcriptomic profiles research, providing a comprehensive understanding of the metabolic alterations and redox adaptation in leukemia. The ability of MV-4-11 cells to respond to various cancer research chemicals, including inhibitors like venetoclax, and their role in studying resistant cells. In conclusion, the MV-4-11 cell line is a crucial tool in leukemia research, offering a versatile platform for investigating the complex biology of acute myeloid leukemia, testing the efficacy of therapeutic agents, and exploring the potential of targeted treatments in overcoming drug resistance.

SKU:BHC11100404

  • Antigen expression: CD4 (40-96%), CD10 (4-11%), CD15 (96-99%)
  • Mutational profile: FLT3mut (a FLT3 internal tandem duplication was verified by PCR)
  • Karyotype: 48, xY, t(4,11)(q21,q23), +8, +19
  • cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
  • supplements: Supplement the medium with 10% FBS
  • subculturing: Maintain cultures by periodically adding or replacing the medium. Initiate cultures with a density of 5 x 105 cells/ml and keep the cell concentration within the range of 3 x 105 to 1 x 106 cells/ml for optimal growth.
  • seedingDensity: 5 x 105 cells/mL
  • postThawRecovery: Please allow the cells to recover from the freezing process for at least 48 hours.
  • freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.
  1. A novel polyethylene glycol ( PEG )‐drug conjugate of Venetoclax, a Bcl‐2 inhibitor, for treatment of acute myeloid leukemia ( AML )Cancer Reports| DOI: 10.1002/cnr2.1485 | PMID: 34173723 | PMC: pmc08955075
  2. SAR Probing of KX2-391 Provided Analogues With Juxtaposed Activity Profile Against Major Oncogenic KinasesFrontiers in Oncology| DOI: 10.3389/fonc.2022.879457 | PMID: 35669422 | PMC: pmc09166630
  3. Synthesis and Antiproliferative Activity of 2,4,6,7-Tetrasubstituted-2 H -pyrazolo[4,3- c ]pyridinesMolecules| DOI: 10.3390/molecules26216747 | PMID: 34771163 | PMC: pmc08588486
  4. Synthesis and Structural Optimization of 2,7,9-Trisubstituted purin-8-ones as FLT3-ITD InhibitorsInternational Journal of Molecular Sciences| DOI: 10.3390/ijms232416169 | PMID: 36555810 | PMC: pmc09782245
  5. Dual FLT3/haspin kinase inhibitor based on 3 H -pyrazolo[4,3- f ]quinoline scaffold with activities against acute myeloid leukemia.RSC medicinal chemistry| DOI: 10.1039/d3md00192j | PMID: 37731695 | PMC: pm37731695
  6. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structure.European journal of medicinal chemistry| DOI: 10.1016/j.ejmech.2021.113309 | PMID: 33711765 | PMC: pm33711765
  7. Targeting BCL-2 and PI3K signaling pathways enhances cytotoxicity of gemtuzumab ozogamicin against acute myeloid leukemia cells.Biochemical and biophysical research communications| DOI: 10.1016/j.bbrc.2026.153752 | PMID: 41980559 | PMC: pm41980559
  8. Chemoenzymatic route to Tyrphostins involving lipase-catalyzed kinetic resolution of 1-phenylethanamine with alkyl cyanoacetates as novel acylating agentsTetrahedron: Asymmetry| DOI: 10.1016/j.tetasy.2015.04.013 | PMC: 10__1016_slash_j__tetasy__2015__04__013
  9. Trifluoromethylcinnamanilides - Effective dual inhibitors of Mycobacterium smegmatis and Plasmodium falciparum.Bioorganic chemistry| DOI: 10.1016/j.bioorg.2024.107957 | PMID: 39615279 | PMC: pm39615279
  10. Imidazo[1,2-c]pyrimidin-5(6H)-one inhibitors of CDK2: Synthesis, kinase inhibition and co-crystal structureEuropean Journal of Medicinal Chemistry| DOI: 10.1016/j.ejmech.2021.113309 | PMC: 10__1016_slash_j__ejmech__2021__113309
  11. Discovery and development of extreme selective inhibitors of the ITD and D835Y mutant FLT3 kinases.European journal of medicinal chemistry| DOI: 10.1016/j.ejmech.2019.111710 | PMID: 31614258 | PMC: pm31614258
  12. Inhibition of FLT3-ITD Kinase in Acute Myeloid Leukemia by New Imidazo[1,2- b ]pyridazine Derivatives Identified by Scaffold HoppingJournal of Medicinal Chemistry| DOI: 10.1021/acs.jmedchem.3c00575 | PMID: 37535845 | PMC: pmc10461230
  13. 3 H -Pyrazolo[4,3- f ]quinoline-Based Kinase Inhibitors Inhibit the Proliferation of Acute Myeloid Leukemia Cells In Vivo.Journal of medicinal chemistry| DOI: 10.1021/acs.jmedchem.1c00330 | PMID: 34288692 | PMC: pm34288692
  14. Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC).European journal of medicinal chemistry| DOI: 10.1016/j.ejmech.2022.114792 | PMID: 36191408 | PMC: pm36191408
  15. Novel water-soluble and highly efficient dual type I/II next generation inhibitors of FMS-like tyrosine kinase 3 (FLT3).European journal of medicinal chemistry| DOI: 10.1016/j.ejmech.2025.117849 | PMID: 40517575 | PMC: pm40517575
  16. 3H-pyrazolo[4,3-f]quinoline hinge binder, a tunable scaffold for development of novel kinase inhibitors against FLT3-driven leukemia.European journal of medicinal chemistry| DOI: 10.1016/j.ejmech.2025.118309 | PMID: 41187563 | PMC: pm41187563
  17. Arylacetamides as AMP-activated protein kinase inhibitors and their use for treatment of breast cancer1666656000 | PMC: us11479536

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Supplier Ads Slides show

Add dynamic ads with slider